Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1996 Dec;49(12):990–993. doi: 10.1136/jcp.49.12.990

Hyperfibrinolysis in hepatosplenic schistosomiasis.

N E el-Bassiouni 1, A E el Bassiouny 1, H R el-Khayat 1, M M Akl 1, S A Omran 1
PMCID: PMC499647  PMID: 9038736

Abstract

AIM: To evaluate the nature of accelerated fibrinolysis in hepatosplenic schistosomiasis. METHODS: The biological activity of plasminogen (Plg), plasminogen activators (PA), alpha 2-antiplasmin (alpha 2-AP) and plasminogen activator inhibitor-1 (PAI-1) was determined by photometric analysis in 15 compensated and 35 decompensated patients with endemic Egyptian hepatosplenomegaly. Quantitative measurement of plasma concentrations of tissue t-PA, t-PA-PAI-1 complex, alpha 2-antiplasmin-plasmin complex (alpha 2-APP), fibrinogen degradation products (FbDP), D-dimers (D-D), thrombin-antithrombin complex (TAT) and prothrombin fragment (F 1 + 2) complexes, using double antibody sandwich enzyme linked immunosorbent assays and grading of the degree of hepatic insufficiency according to the Child-Pugh classification, were also carried out. RESULTS: The progressive deterioration of liver function in schistosomal patients, which matched the severity of the disease, led to simultaneous defects in profibrinolytic (decreased Plg and increased PA and t-PA) and antifibrinolytic (decreased alpha 2-AP and PAI-1) factors-the latter defects being the most prominent-resulting in significant generation of plasmin (increased APP complexes) and therefore enhanced fibrinolysis (increased FbDP and D-dimer). The raised concentrations of FbDP, D-D, TAT and F 1 + 2 established its secondary nature. CONCLUSION: These findings suggest that the amount of PAI-1 available to bind and neutralise circulating t-PA may be a critical factor in the progress of hyperfibrinolysis observed in hepatosplenic schistosomiasis, and that the pronounced reduction in its plasma concentration may be regarded as a potential warning indicator of haemostatic imbalance in decompensated schistosomal patients at high risk of variceal bleeding.

Full text

PDF
990

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amer A. M., el Defrawi I. E., el Sherif N. H., el Khayat H. R. Is the coagulopathy of hepatosplenic schistosomiasis immune-related? Blood Coagul Fibrinolysis. 1994 Oct;5(5):789–793. doi: 10.1097/00001721-199410000-00017. [DOI] [PubMed] [Google Scholar]
  2. Aoki N., Yamanaka T. The alpha2-plasmin inhibitor levels in liver diseases. Clin Chim Acta. 1978 Mar 1;84(1-2):99–105. doi: 10.1016/0009-8981(78)90481-3. [DOI] [PubMed] [Google Scholar]
  3. Bertaglia E., Belmonte P., Vertolli U., Azzurro M., Martines D. Bleeding in cirrhotic patients: a precipitating factor due to intravascular coagulation or to hepatic failure? Haemostasis. 1983;13(5):328–334. doi: 10.1159/000214772. [DOI] [PubMed] [Google Scholar]
  4. Boks A. L., Brommer E. J., Schalm S. W., Van Vliet H. H. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology. 1986 Jan-Feb;6(1):79–86. doi: 10.1002/hep.1840060115. [DOI] [PubMed] [Google Scholar]
  5. Booth N. A., Anderson J. A., Bennett B. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. J Clin Pathol. 1984 Jul;37(7):772–777. doi: 10.1136/jcp.37.7.772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Booth N. A., Anderson J. A., Bennett B. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. J Clin Pathol. 1984 Jul;37(7):772–777. doi: 10.1136/jcp.37.7.772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Booth N. A., Bennett B. Plasmin-alpha 2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis. Br J Haematol. 1984 Apr;56(4):545–556. doi: 10.1111/j.1365-2141.1984.tb02179.x. [DOI] [PubMed] [Google Scholar]
  8. CLAUSS A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957 Apr;17(4):237–246. doi: 10.1159/000205234. [DOI] [PubMed] [Google Scholar]
  9. Conn H. O. A peek at the Child-Turcotte classification. Hepatology. 1981 Nov-Dec;1(6):673–676. doi: 10.1002/hep.1840010617. [DOI] [PubMed] [Google Scholar]
  10. Fitch P., Bennett B., Booth N. A., Croll A., Ewen S. W. Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases. J Clin Pathol. 1994 Mar;47(3):218–221. doi: 10.1136/jcp.47.3.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Francis R. B., Jr, Feinstein D. I. Clinical significance of accelerated fibrinolysis in liver disease. Haemostasis. 1984;14(6):460–465. doi: 10.1159/000215106. [DOI] [PubMed] [Google Scholar]
  12. Hersch S. L., Kunelis T., Francis R. B., Jr The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. Blood. 1987 May;69(5):1315–1319. [PubMed] [Google Scholar]
  13. Holvoet P., Cleemput H., Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost. 1985 Oct 30;54(3):684–687. [PubMed] [Google Scholar]
  14. Kluft C. Studies on the fibrinolytic system in human plasma: quantitative determination of plasminogen activators and proactivators. Thromb Haemost. 1979 Apr 23;41(2):365–383. [PubMed] [Google Scholar]
  15. Koppert P. W., Hoegee-de Nobel E., Nieuwenhuizen W. A monoclonal antibody-based enzyme immunoassay for fibrin degradation products in plasma. Thromb Haemost. 1988 Apr 8;59(2):310–315. [PubMed] [Google Scholar]
  16. Koppert P. W., Koopman J., Haverkate F., Nieuwenhuizen W. Production and characterization of a monoclonal antibody reactive with a specific neoantigenic determinant (comprising B beta 54-118) in degradation products of fibrin and of fibrinogen. Blood. 1986 Aug;68(2):437–441. [PubMed] [Google Scholar]
  17. Leebeek F. W., Kluft C., Knot E. A., de Maat M. P., Wilson J. H. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology. 1991 Nov;101(5):1382–1390. doi: 10.1016/0016-5085(91)90092-y. [DOI] [PubMed] [Google Scholar]
  18. Omran S. A., Madkour B. A., Essawy F. M., Toima S. M., el Kaliouby A. H., Shams el Din A. A. The pathogenesis of accelerated fibrinolysis in hepatosplenic schistosomiasis. Blood Coagul Fibrinolysis. 1992 Dec;3(6):819–822. doi: 10.1097/00001721-199212000-00038. [DOI] [PubMed] [Google Scholar]
  19. Omran S. A., el-Bassiouni N. E., Amer A. M., Hussein A. T. Fibrinolytic parameters during acute haematemesis in endemic hepatosplenomegaly. Blood Coagul Fibrinolysis. 1993 Dec;4(6):891–894. [PubMed] [Google Scholar]
  20. Omran S. A., el-Bassiouni N. E., Hussein N. A., Akl M. M., Hussein A. T., Mohamed A. A. Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis. Haemostasis. 1995 Sep-Oct;25(5):218–228. doi: 10.1159/000217164. [DOI] [PubMed] [Google Scholar]
  21. Pelzer H., Schwarz A., Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost. 1988 Feb 25;59(1):101–106. [PubMed] [Google Scholar]
  22. Pelzer H., Schwarz A., Stüber W. Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide. Thromb Haemost. 1991 Feb 12;65(2):153–159. [PubMed] [Google Scholar]
  23. Pugh R. N., Murray-Lyon I. M., Dawson J. L., Pietroni M. C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973 Aug;60(8):646–649. doi: 10.1002/bjs.1800600817. [DOI] [PubMed] [Google Scholar]
  24. Rijken D. C., van Hinsbergh V. W., Sens E. H. Quantitation of tissue-type plasminogen activator in human endothelial cell cultures by use of an enzyme immunoassay. Thromb Res. 1984 Jan 15;33(2):145–153. doi: 10.1016/0049-3848(84)90175-0. [DOI] [PubMed] [Google Scholar]
  25. Savion N., Farzame N. Binding uptake and degradation of antithrombin III X protease complexes by cultured corneal endothelial cells. Exp Cell Res. 1984 Jul;153(1):50–60. doi: 10.1016/0014-4827(84)90447-6. [DOI] [PubMed] [Google Scholar]
  26. Silverstein R. M. The determination of human plasminogen using Nalpha-CBZ-L-lysin p-nitrophenyl ester as substrate. Anal Biochem. 1975 May 12;65(1-2):500–506. doi: 10.1016/0003-2697(75)90535-7. [DOI] [PubMed] [Google Scholar]
  27. Sprengers E. D., Princen H. M., Kooistra T., van Hinsbergh V. W. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med. 1985 Jun;105(6):751–758. [PubMed] [Google Scholar]
  28. Stief T. W., Lenz P., Becker U., Heimburger N. Determination of plasminogen activator inhibitor (PAI) capacity of human plasma in presence of oxidants: a novel principle. Thromb Res. 1988 May 15;50(4):559–573. doi: 10.1016/0049-3848(88)90204-6. [DOI] [PubMed] [Google Scholar]
  29. Suffredini A. F., Harpel P. C., Parrillo J. E. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med. 1989 May 4;320(18):1165–1172. doi: 10.1056/NEJM198905043201802. [DOI] [PubMed] [Google Scholar]
  30. Teger-Nilsson A. C., Friberger P., Gyzander E. Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. Scand J Clin Lab Invest. 1977 Sep;37(5):403–409. [PubMed] [Google Scholar]
  31. Violi F., Ferro D., Basili S., Quintarelli C., Saliola M., Alessandri C., Cordova C., Balsano F. Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology. 1992 Apr;15(4):672–676. doi: 10.1002/hep.1840150420. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES